Novo Nordisk: Is Novo's central scenario realistic?

NEUTRAL, Fair Value DKK375 vs. DKK390 (+3%)
News published on October Friday 30, 2015
Share on

We have adjusted our FV from DKK390 to DKK375 as a consequence of Sanofi’s comments about the pricing situation in the basal insulin US market and in view of the unclear ones from Novo’s management. Should there be a meaningful paradigm shift, Novo would likely be impacted significantly. For further comments and for a more global view, we will wait for the CMD.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities